Johnson & Johnson
 (JNJ)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Apr. 4, 2013, 4:45 AM
    The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK).
    | Apr. 4, 2013, 4:45 AM | 5 Comments
  • Apr. 3, 2013, 11:51 AM

    Astex Pharmaceuticals (ASTX +12.5%) gets a pop from RBC today, who initiated coverage with an Outperform and a $9 price target, calling it an "undiscovered gem." The firm says the ASTX could have a blockbuster in its pipeline with its experimental blood cancer drug, SGI-110, which is thought to be a safer and more effective version of an already approved therapy it licenses to Eisai (ESALY.PK) and JNJ. ASTX owns all the rights to SGI-110, giving it big upside potential if it gets approved. Additionally, the company reported earlier that it plans to present "significant data" at the AACR annual meeting on Saturday.

    | Apr. 3, 2013, 11:51 AM
  • Apr. 1, 2013, 9:09 AM

    Medical products maker Covidien (COV) says it was awarded $176M as a federal court ruled several patents were infringed by Johnson & Johnson's (JNJ) Ethicon Endo-Surgery unit and its Harmonic line of ultrasonic surgical products.

    | Apr. 1, 2013, 9:09 AM
  • Mar. 31, 2013, 4:14 AM

    The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016.

    | Mar. 31, 2013, 4:14 AM | 5 Comments
  • Mar. 27, 2013, 3:08 PM
    Amgen (AMGN +1%) and Johnson & Johnson (JNJ +0.5%) also hit new 52-week highs today on the back of developments stemming from Kinmed and PFE's non-exclusive partnership.
    | Mar. 27, 2013, 3:08 PM
  • Mar. 26, 2013, 3:32 PM

    Shares of Johnson & Johnson (JNJ +1.5%) are trading at a fresh all-time high today, ratcheting up an ongoing a streak of higher highs since the beginning of the year after UBS ups its price target on the shares from $81.00 to $87.00. If the stock closes out the week above $79.74, this could be it's longest winning streak in at least 20 years.

    | Mar. 26, 2013, 3:32 PM | 6 Comments
  • Mar. 11, 2013, 8:56 AM
    Having been on the wrong end of an $8.3M award over its recalled all-metal ASR hip implants on Friday in LA, J&J (JNJ) is due in a Chicago court today for the start of another trial over the device. Illinois nurse Carol Strum contends that the ASR was defective and that the company didn't warn her of the risks. Overall, J&J faces 10,750 lawsuits related to the implant.
    | Mar. 11, 2013, 8:56 AM | 1 Comment
  • Mar. 10, 2013, 5:00 AM

    With companies looking to avoid paying taxes on their profits, 83 of the largest firms kept $1.46T overseas in 2012, up 14.4% from the previous year, Bloomberg calculates. GE (GE) again had the most with $108B held offshore, up from $102B in 2011; Pfizer was second with $73B, after which came Microsoft (MSFT), Merck (MRK), Johnson & Johnson (JNJ) and IBM (IBM).

    | Mar. 10, 2013, 5:00 AM | 73 Comments
  • Mar. 8, 2013, 4:05 PM

    A court jury in Los Angeles has awarded $8.3M in damages to a man who said he was injured by Johnson & Johnson's (JNJ +0.5%) all-metal hip implants, which the jury found were designed defectively. The verdict ends the first trial of about 10,750 product-liability lawsuits filed against JNJ's DePuy unit, which manufactured the ASR XL hip- replacement devices.

    | Mar. 8, 2013, 4:05 PM | 6 Comments
  • Mar. 6, 2013, 8:51 AM

    SA Author Amit Cohen of Biomed Group delves into the strong initial sales of Medivation's (MDVN) Xtandi treatment for prostate cancer, which was launched in the U.S. in September. Q4 revenues of the drug were $57.4M, while those of J&J's (JNJ) rival product Zytiga fell 16% sequentially. Although Xtandi is more expensive, it has a "number of advantages" over Zytiga.

    | Mar. 6, 2013, 8:51 AM
  • Mar. 5, 2013, 8:27 AM
    The FDA has again rejected expanding the use of J&J's (JNJ) Xarelto blood thinner to patients with acute coronary syndrome, confirming a decision it made in June. The agency is concerned that the drug, which J&J co-markets with Bayer, could cause life-threatening bleeding. However, J&J unit Janssen says that "while we saw an increase in major bleeding, there was no increase in fatal bleeding."
    | Mar. 5, 2013, 8:27 AM
  • Mar. 4, 2013, 3:15 PM

    A combination of Gilead's (GILD +0.6%) Sofosbuvir and Simeprevir, a drug being jointly developed by Medivir (MVRBF.PK) and Johnson & Johnson's (JNJ) Janssen unit, eliminates hepatitis C in all 80 patients in a Phase IIa study. The patients had failed to respond to other treatments. "We went for the most difficult to cure, with the idea if we could show good efficacy there, it could be assumed the regimen could be efficacious in other patient populations," says Gaston Picchio of Medivir partner J&J (JNJ +0.5%). (PR)

    | Mar. 4, 2013, 3:15 PM | 2 Comments
  • Mar. 4, 2013, 9:50 AM

    Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed.

    | Mar. 4, 2013, 9:50 AM
  • Feb. 26, 2013, 10:03 AM
    The award of $3.35M against J&J (JNJ +0.8%) over its vaginal mesh in a case involving a South Dakota patient could have an impact on other suits against the company and rival manufacturers C.R. Bard (BCR +0.3%), Boston Scientific (BSX -0.3%) and Endo Health (ENDP +0.3%). Around 11,000 claims have been consolidated into five cases that are pending in West Virginia.
    | Feb. 26, 2013, 10:03 AM
  • Feb. 26, 2013, 3:19 AM

    A jury is due to start hearing arguments today about the punitive damages that Johnson & Johnson (JNJ) should pay for harm caused to a South Dakota patient by the company's Gynecare Prolift vaginal mesh. The jury yesterday ordered the company to pay Linda Gross $3.35M in an initial award. J&J faces 4,000 lawsuits over the product in the U.S., although Morningstar analyst Damien Conover reckons the firm should be able to withstand any further penalties.

    | Feb. 26, 2013, 3:19 AM
  • Feb. 13, 2013, 8:26 AM

    The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being developed by Pharmacyclics (PCYC +3.7%) and J&J (JNJ), for two rare types of lymphoma. The designation was created last year and could enable drug approval after just an expanded early stage study. The companies  now plan to file for authorization of Ibrutinib by the end of the year. (PR)

    | Feb. 13, 2013, 8:26 AM
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.